PRCT

PROCEPT BioRobotics Corporation develops and commercializes surgical robotic systems for urological procedures, with primary focus on treating benign prostatic hyperplasia (BPH). Headquartered in San Jose, California, the company's flagship product is the AQUABEAM Robotic System, which utilizes personalized image-guided waterjet technology to perform aquablation therapy. This minimally invasive procedure removes prostate tissue with precision while preserving surrounding anatomy, offering an alternative to traditional surgical methods like TURP and laser treatments. PROCEPT markets its technology to hospitals and ambulatory surgery centers across the United States and select international markets. The company went public in September 2021 and trades on the NASDAQ exchange. As of recent filings, PROCEPT employs approximately 400 people and continues to expand its commercial footprint within the urology market. The company generates revenue through system sales and recurring income from handpieces and other disposables used during procedures. Recent developments include expanded Medicare coverage for aquablation therapy and FDA clearance for treating larger prostate sizes up to 150cc, broadening the addressable patient population. PROCEPT faces competition from established medical device companies offering alternative BPH treatments, but differentiates itself through its robotic platform's ability to provide consistent, personalized outcomes. The company remains in growth stage, focusing on increasing procedure volumes and market penetration within the multi-billion dollar BPH treatment market.